Company Overview and News

 
Tata Sponge Iron Limited - Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Updates

2018-08-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Updates

2018-08-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Updates

2018-08-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Proxy advisory firm seeks change in voting rules for related-party transactions

2018-08-15 livemint
Mumbai: Proxy advisory firm Stakeholders Empowerment Services (SES) has asked the Securities and Exchange Board of India (Sebi) to reconsider regulations governing shareholder approval for related-party transactions (RPTs).
513010 500470 TTST TATASTEEL TATLY TATASPONGE

 
Tata Sponge Iron Limited - Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Shareholders meeting

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Financial Results Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Jun qtr net profit rises 49% to Rs 45cr

2018-07-17 moneycontrol
Tata Sponge Iron today reported a 49 percent rise in its consolidated net profit to Rs 45.56 crore for the quarter ended June 30. The company had posted a net profit of Rs 30.57 crore in the corresponding quarter of previous fiscal, Tata Sponge Iron Ltd said in a BSE filing.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Outcome of Board Meeting

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Financial Result Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Tata Sponge Iron Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513010 TATASPONGE

 
Ashok Leyland, ICICI Lombard results

2018-07-16 thehindubusinessline
Nearly two dozen companies, including 8K Miles Software Services, Ashok Leyland, Atishay, Crisil, Federal Bank, Goa Carbon, Hindustan Media Ventures, ICICI Lombard General Insurance, Integrated Capital, Jindal Stainless, Indian Metals & Ferro Alloys, Muthoot Capital Services, Nucleus Software Exports, Rallis India, Sintex Industries, Tata Sponge Iron and Zee Entertainment Enterprises will declare their April-June quarter results on Tuesday.
RALLIS GOACARBON 500469 IDBI 531209 MUTHTFN FEDA TATASPONGE FEDS 500355 JSL 500477 ZEEL FEDERALBNK 509567 ASHOKLEY 513010 500116 IBN 532508 FDBAY FERROALL AKLD 533217 511766 ICICIBANK ZEEEY 532174 SINTEX 502742 505537 500141 AKLS NUCLEUS HMVL

4
Podcast | Pick of the day - NCLT okays Tatas#39; bye bye to Cyrus Mistry

2018-07-09 moneycontrol
It appears there is finally some resolution in the eighteen-month-long battle between the Tata Sons and Cyrus Mistry at the National Company Law Tribunal (NCLT). Today, the NCLT dismissed Cyrus Mistry’s plea for his alleged illegal removal from the post of Tata Sons’ Chairman. And that is our Pick of the Day.
500408 TTML TATACOFFEE 500800 BHUSANSTL TTAZF TTQQY BHRQY TATACOMM TTNQY TATACHEM TTAEY 532301 TGBL 500470 532540 TATAINVEST TATASPONGE 501301 500570 BHARTIARTL TATAMOTORS 500770 500055 513010 TGBA TATAMETALI TATAPOWER 513434 532454 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TATAGLOBAL TTM

4
Tata Group stocks rally 1-5% after NCLT rules in Tata Sons#39; favour in Cyrus Mistry case

2018-07-09 moneycontrol
Tata Group stocks gained on Monday after the National Company Law Tribunal ruled in favour of Tata Sons against Cyrus Mistry's plea with regards to his removal as Tata Sons Chairman.
500408 TTML TTQQY TATACOMM TTNQY TATACHEM 500470 532540 TATAINVEST TATASPONGE 501301 500570 TATAMOTORS 500770 513010 TATAMETALI TATAPOWER 513434 TTST TATASTEEL TATLY 532371 TPCL TATAELXSI TCS 500400 500483 TTM

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

6h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...